Related papers: Bayesian Nonparametric Causal Inference for Quanti…
Neurodegeneration as measured through magnetic resonance imaging (MRI) is recognized as a potential biomarker for diagnosing Alzheimer's disease (AD), but is generally considered less specific than amyloid or tau based biomarkers. Due to a…
As a general and robust alternative to traditional mean regression models, quantile regression avoids the assumption of normally distributed errors, making it a versatile choice when modeling outcomes such as cognitive scores that typically…
Pre-symptomatic (or Preclinical) Alzheimer's Disease is defined by biomarker evidence of fibrillar amyloid beta pathology in the absence of clinical symptoms. Clinical trials in this early phase of disease are challenging due to the slow…
Through Alzheimer's Disease Neuroimaging Initiative (ADNI), time-to-event data: from the pre-dementia state of mild cognitive impairment (MCI) to the diagnosis of Alzheimer's disease (AD), is collected and analyzed by explicitly unraveling…
Medium-horizon Alzheimer's disease progression prediction is difficult because future clinical scores can remain tied to baseline severity, while biomarker histories are irregular and incompletely observed. We develop an anchor-based…
Predicting the risk of clinical progression from cognitively normal (CN) status to mild cognitive impairment (MCI) or Alzheimer's disease (AD) is critical for early intervention in Alzheimer's disease (AD). Traditional survival models often…
Multi-modal biological, imaging, and neuropsychological markers have demonstrated promising performance for distinguishing Alzheimer's disease (AD) patients from cognitively normal elders. However, it remains difficult to early predict when…
The Alzheimer's Disease Neuroimaging Initiative (ADNI) provides a comprehensive multimodal neuroimaging resource for studying aging and Alzheimer's disease (AD). Since its second wave, ADNI has increasingly collected resting-state…
We propose a Bayesian latent variable model to estimate covariate-assisted dependence structures across multiple modalities of multivariate data that may be observed asynchronously. This setting commonly arises in longitudinal biomedical…
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, structural brain changes, and genetic predispositions. This study leverages machine-learning and statistical techniques to investigate…
Alzheimer's disease is one of the most common types of neurodegenerative disease, characterized by the accumulation of amyloid-beta plaque and tau tangles. Recently, deep learning approaches have shown promise in Alzheimer's disease…
Alzheimer's disease (AD) is a neurodegenerative disorder that is beginning with amyloidosis, followed by neuronal loss and deterioration in structure, function, and cognition. The accumulation of amyloid-beta in the brain, measured through…
Alzheimer's Disease is a neurodegenerative condition characterized by dementia and impairment in neurological function. The study primarily focuses on the individuals above age 40, affecting their memory, behavior, and cognitive processes…
Alzheimer's Disease (AD) ravages the cognitive ability of more than 5 million Americans and creates an enormous strain on the health care system. This paper proposes a machine learning predictive model for AD development without medical…
A common neurodegenerative disease, Alzheimer's disease requires a precise diagnosis and efficient treatment, particularly in light of escalating healthcare expenses and the expanding use of artificial intelligence in medical diagnostics.…
Purpose: This study investigates whether a machine-learning-based system can predict the rate of cognitive decline in mildly cognitively impaired patients by processing only the clinical and imaging data collected at the initial visit.…
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder that progressively impairs memory, decision-making, and overall cognitive function. As AD is irreversible, early prediction is critical for timely intervention and…
Dementia of Alzheimer's Type (DAT) is a complex disorder influenced by numerous factors, but it is unclear how each factor contributes to disease progression. An in-depth examination of these factors may yield an accurate estimate of…
Introduction: It is challenging at baseline to predict when and which individuals who meet criteria for mild cognitive impairment (MCI) will ultimately progress to Alzheimer's disease (AD) dementia. Methods: A deep learning method is…
A key issue to Alzheimer's disease clinical trial failures is poor participant selection. Participants have heterogeneous cognitive trajectories and many do not decline during trials, which reduces a study's power to detect treatment…